biostudies-literatureUnknown19(11)Furlaneto FDanisco Sweeteners Oy<h4>Objective</h4>To evaluate the adjunctive use of the probiotic Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019) to conventional therapy on clinical and microbiological parameters in patients with generalized gingivitis.<h4>Methods</h4>Sixty systemically healthy individuals with untreated generalized gingivitis were submitted to periodontal therapy and allocated to receive Placebo (n = 30) or Probiotic (n = 30) lozenges, twice a day for 8 weeks. Bleeding on Marginal Probing (BOMP) was evaluated at baseline, after 2 and 8 weeks. Supra and subgingival biofilm were obtained at baseline and 8 weeks post-therapy for analyses by 16S rRNA gene sequencing. Differences between therapeutic groups were analyzed by non-parametric tests (p<0.05).<h4>Results</h4>The Placebo and ProbioticPloS onee0310529https://www.ebi.ac.uk/biostudies/studies/S-EPMC11554181biostudies-literatureMicrobiological profile of patients with generalized gingivitis undergoing periodontal therapy and administration of Bifidobacterium animalis subsp. lactis HN019: A randomized clinical trial.PMC11554181Salvador SLSColombo APVSilva PHFda Silveira ICFLourenco TGBMessora MRFurlaneto FLevi YLASde Oliveira AMSavio DSFRibeiro MCfalseMicrobiological profile of patients with generalized gingivitis undergoing periodontal therapy and administration of Bifidobacterium animalis subsp. lactis HN019: A randomized clinical trial.<h4>Objective</h4>To evaluate the adjunctive use of the probiotic Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019) to conventional therapy on clinical and microbiological parameters in patients with generalized gingivitis.<h4>Methods</h4>Sixty systemically healthy individuals with untreated generalized gingivitis were submitted to periodontal therapy and allocated to receive Placebo (n = 30) or Probiotic (n = 30) lozenges, twice a day for 8 weeks. Bleeding on Marginal Probing (BOMP) was evaluated at baseline, after 2 and 8 weeks. Supra and subgingival biofilm were obtained at baseline and 8 weeks post-therapy for analyses by 16S rRNA gene sequencing. Differences between therapeutic groups were analyzed by non-parametric tests (p<0.05).<h4>Results</h4>The Placebo and Probiotic2024-01-01T00:00:00Z20242026-06-03T03:17:27.065Z2025-04-06T22:46:11.38ZS-EPMC115541813952760510.1371/journal.pone.0310529